Physician profile
John S Larson
NPI 1144783408
$2,681.88
in general payments reported to CMS, 2019-2025
14 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $167 · 2023: $1,078 · 2024: $801 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.18 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,107.14 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $447.51 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $379.81 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $161.33 | 2023-2025 | Rexulti |
| Alkermes, INC. | $160.52 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $159.36 | 2023-2024 | Invega Sustenna, Invega Trinza, Spravato |
| E.R. Squibb & Sons, L.L.C. | $92.46 | 2024-2025 | Cobenfy |
| Indivior INC. | $56.28 | 2023-2024 | Perseris |
| Lundbeck LLC | $36.09 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.94 | 2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $17.77 | 2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.25 | 2024 | |
| Allergan, INC. | $14.57 | 2021 | |
| Axsome Therapeutics, INC. | $13.85 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.